ReviewMolecules (Basel, Switzerland)2024
Progress in the Study of Natural Antimicrobial Active Substances in
Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- From Rhizosphere to Resistance: Microbe-Plant Interactions in Eco-Smart Biocontrol.MicrobiologyOpen · 2026Review
- Purification, identification, and characterization of a novel bioactive peptide LP-15 with antimicrobial and antioxidant activities produced by Lactobacillus pentosus BL-15 isolated from Asterias.World journal of microbiology & biotechnology · 2026Article
- Mesoporous and magnetic nanoparticle-based delivery of 1-hydroxyphenazine extracted from Pseudomonas aeruginosa enhances antimicrobial activity against different bacterial pathogens.Folia microbiologica · 2026Article
- Nano-selenium mitigates antibiotic resistance in paddy ecosystems via microbiome remodeling and environmental filtering shifts.Applied and environmental microbiology · 2026Article
- A Novel Quinolone JH62 (E-2-(Tridec-4-en-1-yl)-quinolin-4(1H)-one) fromMicroorganisms · 2025Article
- Pseudomonas spp. and antimicrobial resistance: unlocking new horizons with 1-hydroxyphenazine.Folia microbiologica · 2025Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of antimicrobial resistance reduces the effectiveness of antimicrobial drugs in the prevention and treatment of infectious diseases caused by pathogens such as bacteria, fungi, and viruses. Microbial secondary metabolites have been recognized as important sources for new drug discovery and development, yielding a wide range of structurally novel and functionally diverse antimicrobial drugs for the treatment of a variety of diseases that are considered good producers of novel antimicrobial drugs. Bacteria produce a wide variety of antimicrobial compounds, and thus, antibiotics derived from natural products still dominate over purely synthetic antibiotics among the antimicrobial drugs developed and introduced over the last four decades. Among them,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.